NCT05254405View on ClinicalTrials.gov

An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress Disorder

PHASE4RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

March 1, 2026

Conditions
Post-Traumatic Stress Disorder
Interventions
DRUG

Brexanolone Injection [Zulresso]

Continuous infusion of brexanolone over 60 hours titrated to a maximal dose of 90 mcg/kg/hr.

Trial Locations (1)

78712

RECRUITING

University of Texas at Austin Dell Medical School, Austin

Sponsors

Collaborators (1)

Sage Therapeutics
All Listed Sponsors
collaborator

Sage Therapeutics

INDUSTRY

lead

Donald Jeffrey Newport

OTHER

NCT05254405 - An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress Disorder | Biotech Hunter | Biotech Hunter